Metra M, Carubelli V, Ravera A, Stewart Coats AJ (2017) Heart failure 2016: Still more questions than answers. Int J Cardiol 227:766–777. https://doi.org/10.1016/j.ijcard.2016.10.060

Article  PubMed  Google Scholar 

Gevaert AB, Kataria R, Zannad F, Sauer AJ, Damman K, Sharma K, Shah SJ, Van Spall HGC (2022) Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart Br Card Soc 108:1342–1350. https://doi.org/10.1136/heartjnl-2021-319605

Article  Google Scholar 

Nayor M, Houstis NE, Namasivayam M, Rouvina J, Hardin C, Shah RV, Ho JE, Malhotra R, Lewis GD (2020) Impaired exercise tolerance in heart failure with preserved ejection fraction: Quantification of multiorgan system reserve capacity. JACC Heart Fail 8:605–617. https://doi.org/10.1016/j.jchf.2020.03.008

Article  PubMed  PubMed Central  Google Scholar 

Xie Y, Wei Y, Li D, Pu J, Ding H, Zhang X (2023) Mechanisms of SGLT2 inhibitors in heart failure and their clinical value. J Cardiovasc Pharmacol 81:4. https://doi.org/10.1097/FJC.0000000000001380

Article  CAS  PubMed  Google Scholar 

Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM (2017) DEPICT-1 Investigators efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3. Randomised Controlled Trial Lancet Diabetes Endocrinol 5:864–876. https://doi.org/10.1016/S2213-8587(17)30308-X

Article  CAS  PubMed  Google Scholar 

Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero R-M, Woerle H-J, Broedl UC, Johansen OE (2015) SGLT-2 Inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12:90–100. https://doi.org/10.1177/1479164114559852

Article  CAS  PubMed  Google Scholar 

Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC (2014) EMPA-REG H2H-SU trial investigators comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2:691–700. https://doi.org/10.1016/S2213-8587(14)70120-2

Article  CAS  PubMed  Google Scholar 

Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N (2019) SGLT2 Inhibitors: A review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health 16:2965. https://doi.org/10.3390/ijerph16162965

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neal B, Perkovic V, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:2099. https://doi.org/10.1056/NEJMc1712572

Article  PubMed  Google Scholar 

Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, Sreenivasan J, Golzar Y (2018) Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol 25:495–502. https://doi.org/10.1177/2047487318755531

Article  PubMed  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303

Article  CAS  PubMed  Google Scholar 

Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B et al (2019) Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: The DEFINE-HF trial. Circulation 140:1463–1476. https://doi.org/10.1161/CIRCULATIONAHA.119.042929

Article  CAS  PubMed  Google Scholar 

Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G et al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial. Nat Med 27:1954–1960. https://doi.org/10.1038/s41591-021-01536-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah SJ, Voors AA, McMurray JJV, Kitzman DW, Viethen T, Bomfim Wirtz A, Huang E, Pap AF, Solomon SD (2019) Effect of neladenoson bialanate on exercise capacity among patients with heart failure With preserved ejection fraction: A randomized clinical trial. JAMA 321:2101–2112. https://doi.org/10.1001/jama.2019.6717

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wessler BS, Kramer DG, Kelly JL, Trikalinos TA, Kent DM, Konstam MA, Udelson JE (2011) Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. Circ Heart Fail 4:578–588. https://doi.org/10.1161/CIRCHEARTFAILURE.111.961573

Article  CAS  PubMed  Google Scholar 

Pandey A, Shah SJ, Butler J, Kellogg DL, Lewis GD, Forman DE, Mentz RJ, Borlaug BA, Simon MA, Chirinos JA et al (2021) Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC State-of-the-Art review. J Am Coll Cardiol 78:1166–1187. https://doi.org/10.1016/j.jacc.2021.07.014

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Altman DG (2008) Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions; John Wiley & Sons, Ltd, 2008; pp. 187–241 ISBN 978–0–470–71218–4

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan—a web and mobile app for systematic reviews. Syst Rev 5:210. https://doi.org/10.1186/s13643-016-0384-4

Article  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM et al (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898

Article  PubMed  Google Scholar 

Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the Median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13

Article  PubMed  PubMed Central  Google Scholar 

Rohatgi A (2019) WebPlotDigitizer. https://apps.automeris.io/wpd/. Accessed 15 Mar 2024

McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV (2023) Chapter 9: Summarizing Study Characteristics and Preparing for Synthesis. In Cochrane Handbook for Systematic Reviews of Interventions, Cochrane. https://training.cochrane.org/handbook/current/chapter-09. Accessed 15 Mar 2024

10.4.3.1 Recommendations on Testing for Funnel Plot Asymmetry. Available online: https://handbook-5-1.cochrane.org/chapter_10/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm. Accessed 20 Feb 2024.

Lewis GD, Gosch K, Cohen LP, Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Khumri T, Umpierrez G et al (2023) Effect of dapagliflozin on 6-minute walk distance in heart failure with preserved ejection fraction: PRESERVED-HF. Circ Heart Fail 16:e010633. https://doi.org/10.1161/CIRCHEARTFAILURE.123.010633

Article  CAS  PubMed  PubMed Central  Google Scholar 

McMurray JJV, Docherty KF, de Boer RA, Hammarstedt A, Kitzman DW, Kosiborod MN, Maria Langkilde A, Reicher B, Senni M, Shah SJ et al (2023) Effect of dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: The determine randomized clinical trials. Circulation 0. https://doi.org/10.1161/CIRCULATIONAHA.123.065061AQ

Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L et al (2021) Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J 42:700–710. https://doi.org/10.1093/eurheartj/ehaa943

Article  CAS  PubMed  Google Scholar 

Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF et al (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143:516–525. https://doi.org/10.1161/CIRCULATIONAHA.120.052186

Article  CAS  PubMed  Google Scholar 

Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F et al (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 77:243–255. https://doi.org/10.1016/j.jacc.2020.11.008

Article  CAS  PubMed  Google Scholar 

Palau P, Amiguet M, Domínguez E, Sastre C, Mollar A, Seller J, Garcia Pinilla JM, Larumbe A, Valle A, Gómez Doblas JJ et al (2022) Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): A randomized clinical trial. Eur J Heart Fail 24:1816–1826. https://doi.org/10.1002/ejhf.2560

Article  CAS  PubMed  Google Scholar 

Pan D, Xu L, Chen P, Jiang H, Shi D, Guo M (2021) Empagliflozin in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med 22(8):683281. https://doi.org/10.3389/fcvm.2021.683281

Article  CAS  Google Scholar 

Green CP, Porter CB, Bresnahan DR, Spertus JA (2000) Development and evaluation of the kansas city cardiomyopathy questionnaire: A new health status measure for heart failure. J Am Coll Cardiol 35:1245–1255. https://doi.org/10.1016/S0735-1097(00)00531-3

Article  CAS  PubMed  Google Scholar 

Butler J, Filippatos G, Jamal Siddiqi T, Brueckmann M, Böhm M, Chopra VK, Pedro Ferreira J, Januzzi JL, Kaul S, Piña IL et al (2022) Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial. Circulation 145:184–193. https://doi.org/10.1161/CIRCULATIONAHA.121.057812

Article  CAS  PubMed  Google Scholar 

Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J et al (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med 28:568–574. https://doi.org/10.1038/s41591-021-01659-1

Article  CAS